Table 4 Real value analysis of samples with substandard concentrations of the active ingredient
Active ingredient | Place of purchase | Real value analysis (mg) | Difference |
|---|---|---|---|
Chloroquine Phosphate (100 mg) | Private pharmacy | min: 89,94 | 10% |
max: 94,08 | 6% | ||
mid: 91,57 | 8% | ||
Chloroquine Phosphate (100 mg) | marked place | min: 87,32 | 13% |
max: 91,07 | 9% | ||
mid: 88,68 | 11% | ||
Chloroquine Phosphate (250 mg) | marked place | min: 180.16 | 28% |
max: 221.31 | 11% | ||
mid: 200.93 | 20% | ||
Chloroquine Phosphate (250 mg) | marked place | min: 188,01 | 25% |
max: 198,67 | 20% | ||
mid: 193.34 | 23% | ||
Chloroquine Phosphate (250 mg) | marked place | min: 188,38 | 25% |
max: 193,79 | 22% | ||
mid: 191.08 | 24% | ||
Sulfadoxine/Pyrimethamine (500/25 mg) | marked place | only TLC | > 20% |
performed | > 20% | ||
Quinine Sulfate (300 mg) | public health facility | min: 267,42 | 11% |
max: 291,95 | 3% | ||
mid: 277.37 | 7% | ||
Quinine Sulfate (300 mg) | public health facility | min: 176,11 | 41% |
max: 286,60 | 4% | ||
mid: 237.04 | 21% | ||
Quinine Sulfate (300 mg) | Privat pharmacy | min: 251,11 | 16% |
max: 276,09 | 8% | ||
mid: 266.14 | 11% |